What semaglutide is and where it stands with the FDA
Semaglutide is a long-acting copy of GLP-1, a gut hormone your body releases after meals. It is injected under the skin once a week, and it stays active long enough that one dose covers seven days.
As of October 2026, semaglutide is FDA-approved under three brand names. Ozempic (injection) and Rybelsus (tablet) are approved for type 2 diabetes. Wegovy is approved, per its current label, to reduce excess body weight and keep it off, to lower the risk of heart attack and stroke in people with heart disease and excess weight, and to treat a fatty liver disease called MASH. That label now covers a daily Wegovy tablet and a higher 7.2 mg weekly injection, sold as Wegovy HD, for adults who have tolerated 2.4 mg for at least four weeks.
How does semaglutide work?
It works on the GLP-1 receptors in your pancreas, stomach and brain. In the pancreas, it boosts insulin when blood sugar is high and trims glucagon. In the stomach, it slows how fast food empties, so you feel full longer. In the brain, it turns down hunger signals and the constant pull toward food that many men describe as food noise.
The weight result comes mostly from eating less without white-knuckle effort. In the STEP 1 trial, adults on 2.4 mg weekly plus lifestyle coaching lost an average of 14.9 percent of body weight over 68 weeks, versus 2.4 percent with placebo. In the SELECT trial of people with heart disease and excess weight but no diabetes, semaglutide lowered the rate of heart attack, stroke and cardiovascular death by about 20 percent compared with placebo.
For men, two side notes matter. Rapid loss can take muscle with fat, which is why protein and strength training belong in the plan; see muscle loss on semaglutide. And losing weight often nudges testosterone up in men with obesity-related low T, a topic covered in semaglutide and testosterone together.
The 16-week dose escalation
Wegovy starts low and climbs slowly to let your stomach adjust. This is the label schedule, shown as context only: your provider sets your pace and can hold a step if side effects are rough.
| Weeks | Weekly injection dose |
|---|---|
| 1 to 4 | 0.25 mg |
| 5 to 8 | 0.5 mg |
| 9 to 12 | 1 mg |
| 13 to 16 | 1.7 mg |
| 17 onward | 2.4 mg maintenance (1.7 mg if 2.4 mg is not tolerated) |
| Optional step | 7.2 mg (Wegovy HD) after at least 4 weeks on 2.4 mg, if more loss is needed |
The early doses are for tolerance, not weight loss, so slow progress in the first month is expected. Our first 30 days on semaglutide guide covers what that stretch feels like.
Side effects and the warnings to know
Stomach and bowel effects are the most common: nausea, diarrhea, vomiting, constipation and abdominal pain, usually worst after a dose increase. The label also lists headache, fatigue, heartburn, burping and, with the 7.2 mg dose, altered skin sensation (dysesthesia). MedlinePlus has a plain-language list of what to report.
The label’s warnings deserve a straight read:
- Thyroid C-cell tumors (boxed warning). Semaglutide caused these tumors in rodents. Whether it does in people is unknown, but it is not used if you or a family member has had medullary thyroid cancer or if you have MEN 2.
- Gallbladder disease. Gallstones and gallbladder inflammation are more common, partly because of fast weight loss. See GLP-1 gallbladder problems.
- Pancreatitis. Inflammation of the pancreas has occurred, and the drug is stopped if it is suspected.
- Kidney injury from dehydration. Vomiting or diarrhea can dry you out and strain the kidneys.
- Low blood sugar when combined with insulin or sulfonylureas.
- Faster heart rate and aspiration risk under anesthesia, so tell any surgeon or anesthesiologist you take it.
Severe stomach pain that will not go away, with or without vomiting and sometimes spreading to the back, can mean pancreatitis or a gallbladder attack: go to the ER. Swelling of the face or throat or trouble breathing after a dose needs a 911 call.
Why compounded semaglutide now needs a documented reason
During the shortage, compounding pharmacies were allowed to make semaglutide copies. The FDA declared the shortage resolved on February 21, 2025, and its policy update for compounders ended the grace periods in spring 2025. Since then, a 503A pharmacy may make an individualized version only when there is a documented clinical need for that patient, such as an allergy to an ingredient in the branded product. It cannot simply sell a lower-priced copy of the brand.
The FDA also warns about unapproved and counterfeit GLP-1 products, including powders sold “for research use only,” which can contain the wrong ingredient or the wrong amount. Our comparison of compounded semaglutide and Wegovy explains the trade-offs in full.
Monitoring, who should not take it, and how Ultimate Male uses it
Semaglutide is not for you if you have a personal or family history of medullary thyroid cancer, MEN 2, or a prior serious allergic reaction to it. It needs careful thought if you have had pancreatitis, gallbladder disease, severe gastroparesis, diabetic eye disease or kidney problems, or if you use insulin. Monitoring usually covers weight, waist and body composition, blood pressure, heart rate, blood sugar or A1C, kidney function and lipids, plus a check on how much protein you are eating.
At Ultimate Male, semaglutide is one of the two GLP-1 medicines in the medical weight loss program, alongside tirzepatide. Every plan starts with a medical evaluation, blood work before semaglutide or tirzepatide, and body composition analysis, followed by regular check-ins with a PA-C or MD. If you have read about the next wave, such as retatrutide, your provider can explain where it stands and why the clinic sticks with approved options for now.
The clinic is direct-pay, with itemized receipts and financing available, and you get a quote before you commit. Start with a free 10-minute call at 626-319-5261 or read about the semaglutide weight loss program.
